<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351737</url>
  </required_header>
  <id_info>
    <org_study_id>PERSIST Study</org_study_id>
    <nct_id>NCT04351737</nct_id>
  </id_info>
  <brief_title>Dextenza for Post-operative Treatment of Pterygium</brief_title>
  <acronym>PERSIST</acronym>
  <official_title>DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation ComparEd to StandaRd of Care Topical Cortico-Steroid Treatment In PatientS Who Undergo BilaTeral Pterygium Surgery PERSIST Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brandon Eye Associates, PA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brandon Eye Associates, PA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation Compared to Standard of
      Care Topical Cortico-steroid Treatment in Patients who Undergo Bilateral Pterygium Surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients who undergo bilateral pterygium surgery, eyes will be randomized to receive
      either DEXTENZA at baseline, Month 1 and Month 2 or prednisolone x 3 months. Both eyes will
      receive antibiotic drops four times per day for two weeks and Maxitrol ointment at bedtime
      for two weeks following surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>In patients who undergo bilateral pterygium surgery, eyes will be randomized to receive either DEXTENZA at baseline, Month 1 and Month 2 or prednisolone x 3 months. Both eyes will receive antibiotic drops four times per day for two weeks and Maxitrol ointment at bedtime for two weeks following surgery.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient pain level follow pterygium removal</measure>
    <time_frame>2 months</time_frame>
    <description>measurement of pain following pterygium removal using the validated &quot;Numeric Pain Rating Scale&quot; to assess pain, which ranges from 0 to 10 with higher values indicating more severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammation</measure>
    <time_frame>2 months</time_frame>
    <description>measurement of ocular surface inflammation using the standard 1+ - 4+ rating scale commonly used in ophthalmology with 4+ indicating the most inflammation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pterygium of Both Eyes</condition>
  <arm_group>
    <arm_group_label>Pterygium patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with bilateral pterytium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intracanalicular Dexamethasone, (0.4 mg) Insert</intervention_name>
    <description>To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.</description>
    <arm_group_label>Pterygium patients</arm_group_label>
    <other_name>Dextenza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate</intervention_name>
    <description>To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.</description>
    <arm_group_label>Pterygium patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: patients with bilateral pterygium -

        Exclusion Criteria: none

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Fleshner, AA</last_name>
    <phone>8136842211</phone>
    <phone_ext>125</phone_ext>
    <email>mfleshner@brandoneyeassociates.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haroon Ilyas, MD</last_name>
    <phone>8136842211</phone>
    <email>haroonmd@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brandon Eye Associates</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Fleshner, AA</last_name>
      <phone>813-684-2211</phone>
      <phone_ext>8136842211</phone_ext>
      <email>mfleshner@brandoneyeassociates.com</email>
    </contact>
    <contact_backup>
      <last_name>Haroon Ilyas, MD</last_name>
      <phone>8136842211</phone>
      <email>haroonmd@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

